Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis.
Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis. Cardiovasc Hematol Disord Drug Targets. 2015;15(2):92-6 Authors: Akin M, Schäfer A, Akin I, Widder J, Brehm M Abstract Thrombo-embolism of the venous system consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE) is common and associated with high morbidity and mortality. Symptomatic venous thrombembolism (VTE) manifests in about 1/3 of cases as PE and 2/3 as DVT. There is a strongly compound between early mortality after venous VTE and PE, age, malignancies and cardiovascular diseases. Anticoagulation therapy is the main therapeutic approach for the treatment of acute VTE and to prevent recurrent VTE events. For decade's classic anticoagulants like heparin, low-molecular-weight heparins (LMWHs), fondaparinux, and vitamin K antagonists have been the gold standards in therapy and are widely used. Novel oral anticoagulants (NOAC) like the direct thrombin inhibitor (dabigatran etexilate) and the direct factor Xa inhibitors (e.g. rivaroxaban, apixaban, and edoxaban) have been introduced to overcome the drawbacks of vitamin K antagonists. The efficacy and safety of these NOAC have been investigated in several randomized trials. Here we want to give an overview about the NOACS in the treatment of acute and chronic VTE and their use for primary prevention of acute VTE. PMID: 26666324 [PubMed - in process]
(American Roentgen Ray Society) According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize. Due to the differences in clinical prognosis and subsequent management strategies, in situ PAT associated with RT -- which has not previously been described in the English literature -- must be distinguished from pulmonary embolism.
We present a case of pulmonary artery sarcoma in a 54-year-old male, who was clinically misdiagnosed as pulmonary thromboembolism. The patient died of disease; however, the actual diagnosis of PAS was made after a medicolegal autopsy. PAS can be a diagnostic challenge for both clinicians and pathologists. In an autopsy case with a clinical suspicion of pulmonary thromboembolism, if there is an abnormal gross appearance in the pulmonary artery, the forensic pathologist should have a high index of suspicion of PAS, which should be ruled out by a histopathologic examination. PMID: 33031598 [PubMed - as supplied by publisher]
Abstract Pulmonary arterial hypertension (PAH) is a progressive disease characterized by endothelial dysfunction and vascular remodeling. Despite significant advancement in our understanding of the pathogenesis of PAH in recent years, treatment options for PAH are limited and their prognosis remains poor. PAH is now seen as a severe pulmonary arterial vasculopathy with structural changes driven by excessive vascular proliferation and inflammation. Perturbations of a number of cellular and molecular mechanisms have been described, including pathways involving growth factors, cytokines, metabolic signaling, elastase...
Necrotizing pancreatitis (NP) patients have rates of venous thromboembolism (VTE) among the highest of any hospitalized patient (57%). We hypothesized that VTE prophylaxis may be inadequate in the setting of this profound inflammatory disease and that early detection of deep vein thrombosis would limit pulmonary embolism.
Authors: Haque S, Jawed A, Akhter N, Dar SA, Khan F, Mandal RK, Areeshi MY, Lohani M, Wahid M PMID: 33015764 [PubMed - in process]
Recently, computed tomography pulmonary angiography (CTPA) has emerged as the first line modality for the diagnosis of pulmonary embolism (PE) as it is fast, reliable and widely available . However, with increasing use of CTPA, there has been an associated increase in the incidence of PE with no significant change in mortality . Overuse of CTPA leads to unnecessary radiation and contrast exposure, increased costs, as well as incidental findings, raising the question of over-diagnosis of clinically insignificant PEs conferring a major burden on both patients and healthcare system (2,3).
The safety and efficacy of direct oral anticoagulants (DOACs) in intermediate-high risk pulmonary embolism (PE) are unknown. The aims of the present study were to describe outcomes of patients receiving early apixaban or rivaroxaban prescription rather the recommended delayed prescription strategy.
Frail older surgical patients face more than a two-fold increase in postoperative complications, including myocardial infarction, deep vein thrombosis, pulmonary embolism, pneumonia, ileus, and others. Many of...
AbstractAlthough many clinical reports have been published, little is known about the pathological post-mortem findings from people who have died of the novel coronavirus disease. The need for postmortem information is urgent to improve patient management of mild and severe illness, and treatment strategies. The present systematic review was carried out according to the Preferred Reporting Items for Systematic Review (PRISMA) standards. A systematic literature search and a critical review of the collected studies were conducted. An electronic search of PubMed, Science Direct Scopus, Google Scholar, and Excerpta Medica Data...